Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionano Genomics, Inc. (NASDAQ:BNGO ) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Trevor Levy - H.C.

Bionano Genomics, Inc. (BNGO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022. A pre-recorded presentation will be available on the Investor Resources page of the Company's website on Monday, September 12 at 7:00 am ET.

Bionano Genomics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

OrganiGram Holdings Inc.

Bionano Genomics and OrganiGram Holdings are both on track for long-term success.

These 2 Penny Stocks Have Tantalizing Growth Prospects

Amazon

Aurora Innovation

Best Buy

Darling Ingredients

Plug Power

Rivian Automotive

This looks like a wonderful time for investors looking for hot growth stocks with very strong outlooks. I believe that the market is really starting to internalize the concept that Fed Chairman Jerome Powell is anything but super-hawkish on interest rates and that the economy is well-positioned for a “soft landing.

7 Hot Growth Stocks Poised to Triple by 2030

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity. Researchers aimed to determine whether poor prognostic outcomes observed in cases with cth might be related not only to the chromothriptic event itself but also to the presence of complex karyotypes or TP53 abnormalities.

Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Canopy Growth

SmileDirectClub

Penny stocks to buy? Short squeeze stocks to watch this week.

Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch

Following brewing clinical momentum, shares of Bionano Genomics (NASDAQ: BNGO ) — a biotechnology firm specializing in nanoscale imaging and analytics — soared on Thursday. This came after the company announced the publication of a new study.

Why Is Bionano Genomics (BNGO) Stock Up 20% Today?

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics' Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q2 2022 Results - Earnings Call Transcript

Biotechnology firm Bionano Genomic (NASDAQ: BNGO ), which specializes in the development of a nanoscale imaging and analytics platform, generated significant headlines when it announced the results of its landmark research evaluating the utility of optical genome mapping (OGM) myelodysplastic syndrome (MDS). Essentially, the OGM methodology detected higher incidences of pathogenic elements compared to traditional mapping mechanisms, thus bolstering BNGO stock on the very positive implications for delivering superior results.

Bionano Genomic (BNGO) Stock Pops on Research Study

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) for myelodysplastic syndrome (MDS) prognostication. In the peer-reviewed study, published in Leukemia, researchers from The University of Texas MD Anderson Cancer Center reported that when OGM was used instead of karyotyping, 17 to 21% of study subjects had different prognostic risk scores and in 13% of study subjects additional pathogenic variants were revealed. The OGM results were also compared to results of a next-generation sequencing (NGS) panel used for molecular pathology. The comparison to NGS showed that the utility of OGM above and beyond that of karyotyping is not provided by NGS.

Bionano Genomics Announces Publication of Landmark Research Study in Myelodysplastic Syndrome Showing OGM Data would Result in Revised Prognostic Risk Classification or Additional Actionable Variants in 28% of Study Participants

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, August 4th, 2022 at 4:30 p.m. Eastern Time to report financial results for the second quarter 2022 and to highlight recent corporate progress.

Bionano Genomics to Report Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline

Cyclacel Pharmaceuticals

Nu Holdings

Penny stocks to buy according to analysts. The post What Are Penny Stocks & 3 To Buy According To Analysts In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Are Penny Stocks & 3 To Buy According To Analysts In July

Freeport-McMoRan

General Electric

Schrodinger 

Shoals Technologies Group

With the stock market pricing in a recession that likely won't arrive anytime soon, these are some of the best stocks to buy on a dip. The post The 7 Best Stocks to Buy on a Dip in July appeared first on InvestorPlace.

The 7 Best Stocks to Buy on a Dip in July

Ideanomics Inc

Vroom

Use these methods for finding penny stocks to buy in 2022 The post How to Find Penny Stocks to Buy in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find Penny Stocks to Buy in 2022

9 Meters Biopharma

Toughbuilt Industries Inc

Here's what you need to know about trading penny stocks on June 24th The post What to Know About Buying Penny Stocks on June 24th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 24th

My first article on Bionano Genomics was negative as the stock price did a meme-stock bounce far ahead of reality. I traded the stock below $1 hitting my short-term profit goal, then watched it spike into the teens, with some saying it would go to $100 a share.

I'm More Positive But Selling Puts Instead Of Buying Bionano Genomics

Outlook Therapeutics Inc

Qudian

View

Penny stocks to watch right now. The post 4 Hot Penny Stocks To Watch After Big June 2022 News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Watch After Big June 2022 News

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the European Society of Human Genetics (ESHG) 2022 Conference, with 13 scientific and poster presentations highlighting the application of OGM across rare undiagnosed genetic disease and genetic disorders. Additionally, Bionano and Hamilton will present the Long String VANTAGE, the world's first automation solution for UHMW extraction used in OGM.

Bionano Genomics Announces Participation at the European Society of Human Genetics Conference (ESHG) 2022 Featuring OGM Across a Broad Range of Clinical Research Applications and a Collaborative Product Development with Hamilton

Among the stocks that could double in the remainder of 2022 are Bionano , Rivian, and Plug Power. The outlook of all three is very strong.

3 Stocks That Could Double in 2022

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that researchers from University Health Network in Toronto, Columbia University Medical Center, and Children's Hospital of Eastern Ontario will deliver a two-hour presentation on technologies and applications of OGM for genetic research at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022. The CCMG conference will be held virtually this year and runs from June 6-10, 2022.

Bionano Genomics Announces Canadian College of Medical Geneticists Presentation Featuring Applications of OGM for Genetic Research

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that Glass Lewis & Co., a leading independent proxy advisory firm, has recommended that Bionano's stockholders vote in favor of all proposals recommended by Bionano's Board of Directors at the Company's 2022 Annual Meeting of Stockholders (details below).

Bionano Announces Glass Lewis Recommendation and Encourages Stockholders to Cast their Vote Ahead of June 9th Annual Meeting

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of the first peer-reviewed research study using optical genome mapping (OGM) to analyze genetic aberrations found in pediatric patients with acute myeloid leukemia (AML). This research demonstrates the use of OGM to identify minimal residual disease (MRD) markers and other novel variants that can impact therapeutic treatment and case management for pediatric AML patients. MRD markers can be followed over the course of treatment and used to determine whether treatment is working or whether the patient has relapsed.

First Published Study of OGM in Pediatric AML Shows OGM Identifies MRD Markers and other Novel Variants that Can Impact Case Management

Eos Energy Enterprises

BitNile Holdings

Here's what you need to know about buying penny stocks today The post What to Know About Buying Penny Stocks on May 19th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on May 19th

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, will present a company overview available for on-demand listening starting Tuesday, May 24, 2022, at 7:00 a.m. Eastern Time. Interested parties can register for the conference and view the presentation here: www.hcwevents.com/globalconference.

News for Bionano Genomics Stock (BNGO)